Avaxim 80U Active immunisation against infection caused by HAV in childn 12 mth-15 yr. Avaxim 160U Prevention of infection caused by HAV in adults & adolescents from 16 yr.
Avaxim 80U 0.5 mL IM inj followed by booster dose preferably 6-36 mth after primary vaccination & may be administered up to 7 yr after primary vaccination. Avaxim 160U 0.5 mL IM inj followed by booster dose preferably between 6-12 mth after 1st vaccination & may be administered up to 36 mth after 1st vaccination.
Anaphylactic reaction. Not to be inj intravascularly, intradermally or into buttocks. Not for protection against infection caused by HBV, HCV, hepatitis E virus or other known liver pathogens. Syncope; thrombocytopenia or risk of haemorrhage; phenylketonuria. Immunodeficiency or on immunosuppressive treatment. Hepatic disease. Not to be used during pregnancy & lactation.
Sign Out
 160 U_0.5 mL77ae44ca-fb83-400d-b009-a7b40098b289.GIF)
 80 U_0.5 mLc8087fd3-8519-4c1c-9c98-a6b400cd47f4.GIF)
